BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 33044009)

  • 1. Uterine sarcoma with posterior reversible encephalopathy syndrome associated with pazopanib.
    Tatsumichi T; Tanaka H; Okazaki T; Takahashi K; Suzuki K; Kawakita K; Houchi H; Kuroda Y; Kosaka S
    J Clin Pharm Ther; 2021 Feb; 46(1):223-226. PubMed ID: 33044009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Posterior reversible encephalopathy syndrome (PRES) induced by pazopanib, a multi-targeting tyrosine kinase inhibitor, in a patient with soft-tissue sarcoma: case report and review of the literature.
    Deguchi S; Mitsuya K; Nakasu Y; Hayashi N; Katagiri H; Murata H; Wasa J; Takahashi M; Endo M
    Invest New Drugs; 2018 Apr; 36(2):346-349. PubMed ID: 29067537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Posterior Reversible Encephalopathy Syndrome With Concurrent Nephrotic Syndrome in a Patient Treated With Pazopanib for Metastatic Renal Cell Carcinoma: Case Report and Review of the Literature.
    Miaris N; Maltezou M; Papaxoinis G; Visvikis A; Samantas E
    Clin Genitourin Cancer; 2017 Feb; 15(1):e99-e103. PubMed ID: 27601362
    [No Abstract]   [Full Text] [Related]  

  • 4. Pazopanib-associated posterior reversible encephalopathy syndrome with intracerebral haemorrhage.
    Miller-Patterson C; Fehnel CR
    BMJ Case Rep; 2017 Apr; 2017():. PubMed ID: 28416534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Posterior reversible encephalopathy syndrome induced by pazopanib for renal cell carcinoma.
    Asaithambi G; Peters BR; Hurliman E; Moran BP; Khan AS; Taylor RA
    J Clin Pharm Ther; 2013 Apr; 38(2):175-6. PubMed ID: 23210935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversible posterior leukoencephalopathy syndrome induced by pazopanib.
    Chelis L; Souftas V; Amarantidis K; Xenidis N; Chamalidou E; Dimopoulos P; Michailidis P; Christakidis E; Prassopoulos P; Kakolyris S
    BMC Cancer; 2012 Oct; 12():489. PubMed ID: 23088634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pazopanib induced unilateral posterior reversible encephalopathy syndrome.
    Arslan BM; Bajrami A; Demir E; Cabalar M; Yayla V
    Ideggyogy Sz; 2017 Mar; 70(3-4):140-144. PubMed ID: 29870619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination therapy with pazopanib and tivantinib modulates VEGF and c-MET levels in refractory advanced solid tumors.
    Kummar S; Srivastava AK; Navas T; Cecchi F; Lee YH; Bottaro DP; Park SR; Do KT; Jeong W; Johnson BC; Voth AR; Rubinstein L; Wright JJ; Parchment RE; Doroshow JH; Chen AP
    Invest New Drugs; 2021 Dec; 39(6):1577-1586. PubMed ID: 34180036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms Underlying Vascular Endothelial Growth Factor Receptor Inhibition-Induced Hypertension: The HYPAZ Trial.
    Mäki-Petäjä KM; McGeoch A; Yang LL; Hubsch A; McEniery CM; Meyer PAR; Mir F; Gajendragadkar P; Ramenatte N; Anandappa G; Santos Franco S; Bond SJ; Schönlieb CB; Boink Y; Brune C; Wilkinson IB; Jodrell DI; Cheriyan J
    Hypertension; 2021 May; 77(5):1591-1599. PubMed ID: 33775123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of pazopanib in patients with metastatic or unresectable chemoresistant sarcomas: A Japanese Musculoskeletal Oncology Group study.
    Urakawa H; Kawai A; Goto T; Hiraga H; Ozaki T; Tsuchiya H; Nakayama R; Naka N; Matsumoto Y; Kobayashi E; Okuma T; Kunisada T; Ando M; Ueda T; Nishida Y
    Cancer Sci; 2020 Sep; 111(9):3303-3312. PubMed ID: 32579783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-line pazopanib in intermediate- and poor-risk patients with metastatic renal cell carcinoma: Final results of the FLIPPER trial.
    Staehler M; Panic A; Goebell PJ; Merling M; Potthoff K; Herrmann E; de Geeter P; Vannier C; Hogrefe C; Marschner N; Grünwald V
    Int J Cancer; 2021 Feb; 148(4):950-960. PubMed ID: 32738823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses.
    Cesne AL; Bauer S; Demetri GD; Han G; Dezzani L; Ahmad Q; Blay JY; Judson I; Schöffski P; Aglietta M; Hohenberger P; Gelderblom H
    BMC Cancer; 2019 Aug; 19(1):794. PubMed ID: 31409302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of pazopanib for local and lung metastases in Stewart-Treves syndrome.
    Hayashi M; Makino T; Mori N; Mizawa M; Shimizu T
    Eur J Dermatol; 2020 Feb; 30(1):68-69. PubMed ID: 32250262
    [No Abstract]   [Full Text] [Related]  

  • 14. Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas: subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072.
    Kasper B; Sleijfer S; Litière S; Marreaud S; Verweij J; Hodge RA; Bauer S; Kerst JM; van der Graaf WTA
    Ann Oncol; 2014 Mar; 25(3):719-724. PubMed ID: 24504442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bronchopleural fistula arising after commencement of pazopanib for progressive sarcoma.
    Cohen L; Neuhaus S; Chryssidis S; Kotasek D
    ANZ J Surg; 2017 Jul; 87(7-8):E48-E49. PubMed ID: 25556827
    [No Abstract]   [Full Text] [Related]  

  • 16. Outcome of uterine sarcoma patients treated with pazopanib: A retrospective analysis based on two European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) clinical trials 62043 and 62072.
    Benson C; Ray-Coquard I; Sleijfer S; Litière S; Blay JY; Le Cesne A; Papai Z; Judson I; Schöffski P; Chawla S; Gil T; Piperno-Neumann S; Marréaud S; Dewji MR; van der Graaf WTA
    Gynecol Oncol; 2016 Jul; 142(1):89-94. PubMed ID: 27012429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-World Outcomes of Pazopanib Treatment in Korean Patients with Advanced Soft Tissue Sarcoma: A Multicenter Retrospective Cohort Study.
    Oh CR; Hong JY; Kim JH; Lee JS; Kim HS; Kim TW; Ahn JH; Kim JE
    Target Oncol; 2020 Aug; 15(4):485-493. PubMed ID: 32607656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Pazopanib in patients with metastatic uterine sarcoma: A multi-institutional study.
    Sunar V; Korkmaz V; Akin S; Can Guven D; Arik Z; Ates O; Yilmaz M; Mutlu Meydanli M; Oksuzoglu B
    J BUON; 2019; 24(6):2327-2332. PubMed ID: 31983102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Atrial flutter probably related to pazopanib: A case report].
    Puebla Villaescusa A; Díaz Gómez E; Salcedo Mingoarranz ÁL; Ramírez Cruz S; Hidalgo Correas FJ; García Díaz B
    Farm Hosp; 2018 Jan; 42(1):33-34. PubMed ID: 29306315
    [No Abstract]   [Full Text] [Related]  

  • 20. [Pazopanib for treatment of renal cell carcinoma and soft tissue sarcomas].
    Brotelle T; Bay JO
    Bull Cancer; 2014 Jun; 101(6):641-6. PubMed ID: 24977453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.